When you have fibromyalgia (FMS) or chronic fatigue syndrome (CFS or ME/CFS), it's common for well-meaning people to say things like, "If you'd just exercise more, you'd feel better." Research points ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...

Fibromyalgia can make your skin sensitive to the clothes you wear. For some people with this condition, the simple scraping of fabric against the skin can set off burning sensations or sharp, stabbing ...

Fibromyalgia is a chronic condition featuring widespread pain and fatigue. It occurs frequently alongside bipolar disorder, a mental health condition characterized by dramatic shifts in energy and ...

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...

Dec. 22, 2023 — There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia. Both forms of treatment produced a ...

Fibromyalgia, the chronic pain condition that plagues approximately ten million Americans is in need of new drug treatment options. The existing approved drugs on the market often aren't enough ...

TNX-102 SL was granted Fast Track designation for fibromyalgia by the FDA in July of 2024. Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill ...

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. The FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action ...

Click here for a 6-minute video of Seth Lederman, MD, reviewing the status of TNX 102-SL for fibromyalgia Opioids come with their own set of problems. Opioids can be addictive and, over time ...

If the NDA is accepted, Tonix said the FDA could commit to a decision on approval in 2025, which means TNX-102 SL could be on the market as early as next year, giving fibromyalgia sufferers a much ...